Catherine C. Park, M.D.
Professor and Chair
Department of Radiation Oncology
University of California, San Francisco
Dr. Catherine Park is a radiation oncologist with a special interest in the treatment of lymphoma and breast cancer. She earned a medical degree at the UCLA School of Medicine and completed a residency in radiation oncology at the Joint Center for Radiation Oncology at Harvard Medical School. After serving as a visiting scientist at the Lawrence Berkeley National Laboratory, Dr. Park joined UCSF Medical Center.
She is the recipient of numerous awards, including the Upjohn Achievement Award and C. Donald O'Malley Prize in the History of Medicine.
|1989||University of California, Berkeley||BA||History of Art|
|1995-1996||Beth Israel Hospital, Harvard Medical School||Intern|
|1996-2000||Joint Center for Radiation Therapy, Harvard Medical School||Resident|
|1998-1999||Lawrence Berkeley National Laboratory||Research Fellow|
|2014-present||UCSF||Professor in Residence||Radiation Oncology|
|2006-present||Lawrence Berkeley National Laboratory||Faculty Biologist||Division of Life Sciences|
|2008-2014||UCSF||Associate Professor in Residence||Radiation Oncology|
|2005-2008||UCSF||Assistant Professor in Residence||Radiation Oncology|
|2000-2005||UCSF||Assistant Clinical Professor||Radiation Oncology|
|2000-2006||Lawrence Berkeley National Laboratory||Visiting Scientist||Division of Life Sciences|
Awards & Honors
|1995||Alpha Omega Alpha|
|1995||AMWA Janet M. Glasgow Memorial Achievement Citation|
|1995||C. Donald O'Malley Prize in the History of Medicine|
|1995||Dean's Scholar, Thesis Program UCLA School of Medicine|
|1995||Upjohn Achievement Award for Excellence in Research|
|2002||Career Development Award, Breast SPORE, UCSF|
|2002||Junior Investigator Award, International Society for Differentiation, Lyon, France|
|2003||Junior Investigator Award, European Society for Therapeutic Radiation Oncology, Copenhagen, DK|
|2003||Basic Science Junior Investigator Award, American Society for Therapeutic Radiation Oncology, Salt Lake City, UT|
|2003||Junior Faculty Award, AACR Clinical Protocol Workshop, Vail, CO|
|2005||Association of American Medical Colleges Early Career Faculty Womens Professional Development Seminar, Santa Fe, NM|
Park CC, Georgescu W, Polyzos A, Pham C, Ahmed KM, Zhang H, Costes SV. Rapid and automated multidimensional fluorescence microscopy profiling of 3D human breast cultures. Integr Biol (Camb). 2013 Apr 25;5(4):681-91.
Peled AW, Foster RD, Esserman LJ, Park CC, Hwang ES, Fowble B. Increasing the time to expander-implant exchange after postmastectomy radiation therapy reduces expander-implant failure. Plast Reconstr Surg. 2012 Sep;130(3):503-9.
Huang C, Park CC, Hilsenbeck SG, Ward R, Rimawi MF, Wang YC, Shou J, Bissell MJ, Osborne CK, Schiff R. β1 integrin mediates an alternative survival pathway in breast cancer cells resistant to lapatinib. Breast Cancer Res. 2011 Aug 31;13(4):R84.
Nabavizadeh N, Klifa C, Newitt D, Lu Y, Chen YY, Hsu H, Fisher C, Tokayasu T, Olshen AB, Spellman P, Gray JW, Hylton N, Park CC. Topographic enhancement mapping of the cancer-associated breast stroma using breast MRI. Integr Biol (Camb). 2011 Apr;3(4):490-6.
Nam JM, Onodera Y, Bissell MJ, Park CC. Breast cancer cells in three-dimensional culture display an enhanced radioresponse after coordinate targeting of integrin alpha5beta1 and fibronectin. Cancer Res. 2010 Jul 1;70(13):5238-48.
Park CC, Yom SS, Podgorsak MB, Harris E, Price RA Jr, Bevan A, Pouliot J, Konski AA, Wallner PE; Electronic Brachytherapy Working Group. American Society for Therapeutic Radiology and Oncology (ASTRO) Emerging Technology Committee report on electronic brachytherapy. Int J Radiat Oncol Biol Phys. 2010 Mar 15;76(4):963-72.
Weigelt B, Lo AT, Park CC, Gray JW, Bissell MJ. HER2 signaling pathway activation and response of breast cancer cells to HER2-targeting agents is dependent strongly on the 3D microenvironment. Breast Cancer Res Treat. 2010 Jul;122(1):35-43.